Gefapixant

From WikiProjectMed

Chemical compound

Pharmaceutical compound

Gefapixant
Clinical data

Trade names	Lyfnua
Other names	MK-7264
ATC code	R05DB29 (WHO)
Legal status
Legal status	EU: Rx-only [1]
Identifiers
IUPAC name 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS Number	1015787-98-0
PubChemCID	24764487
DrugBank	DB15097
ChemSpider	58828660
UNII	6K6L7E3F1L
KEGG	D11349
ChEMBL	ChEMBL3716057
CompTox Dashboard(EPA)	DTXSID401337212
ECHA InfoCard	100.258.106
Chemical and physical data
Formula	C₁₄H₁₉N₅O₄S
Molar mass	353.40 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19) Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

Gefapixant, sold under the brand nameLyfnua, is a medication used to treatchronic (long-term) cough.^[1] It acts as anantagonist of theP2RX3 receptor.^[2]^[3]^[4]

It was authorized for medical use in the European Union in September 2023.^[1]

Medical uses

Gefapixant isindicated for the treatment of refractory or unexplained chronic cough.^[1]

It was named in honour ofGeoff Burnstock.^[5]

^^a ^b ^c ^d"Lyfnua EPAR".European Medicines Agency. 29 September 2023. Retrieved5 October 2023.
^Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough".Pulmonary Pharmacology & Therapeutics.56:75–78.doi:10.1016/j.pupt.2019.03.006.PMID 30880151.S2CID 81982653.
^Richards D, Gever JR, Ford AP, Fountain SJ (July 2019)."Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation".British Journal of Pharmacology.176 (13):2279–2291.doi:10.1111/bph.14677.PMC 6555852.PMID 30927255.
^Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications".Expert Opinion on Therapeutic Patents.29 (12):943–963.doi:10.1080/13543776.2019.1693542.hdl:11581/435751.PMID 31726893.S2CID 208037373.
^Ford AP, Dillon MP, Kitt MM, Gever JR (November 2021). "The discovery and development of gefapixant".Autonomic Neuroscience.235: 102859.doi:10.1016/j.autneu.2021.102859.PMID 34403981.S2CID 236524967.

Opium alkaloids, opioids, and derivatives	Acetyldihydrocodeine Benzylmorphine Butorphanol Codeine^# (+guaifenesin) Dextromethorphan Dihydrocodeine Dimemorfan Ethylmorphine Heroin Hydrocodone (+guaifenesin,+homatropine) Hydromorphone Laudanum Levomethadone Levopropoxyphene Methadone Nicocodeine Nicodicodeine Normethadone Noscapine Pholcodine Thebacon
Other	Alloclamide Benproperine Benzonatate Bibenzonium bromide Butamirate Clobutinol Clofedanol Cloperastine Dibunate Dimethoxanate Diphenhydramine Dropropizine Droxypropine Fedrilate Fominoben Gefapixant Glaucine Isoaminile Levodropropizine Meprotixol Moguisteine Morclofone Nepinalone Oxeladin Oxolamine Pentoxyverine Pipazetate Piperidione Prenoxdiazine Tipepidine Zipeprol

Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it.